2 domains / 4 areas / 2 specializations
Johnson & Johnson
Also known as: Johnson & Johnson
Data updated
Johnson & Johnson is a publicly traded global healthcare company rather than a venture fund or dedicated asset manager. Its business spans pharmaceuticals and medical technology, and the company is based in New Brunswick, New Jersey, United States.
In the psychedelic ecosystem, Johnson & Johnson matters mainly through its neuroscience and psychiatry-adjacent pharmaceutical activity rather than as a standalone investor. Its acquisition of Intra-Cellular Therapies, a CNS-focused biopharma, shows continued interest in neuropsychiatric therapeutics and related clinical-stage assets.
Academic Research
0 papersPublished Papers
0
Trial Involvement
2
Distinct Focus Topics
0
Latest Publication
Unknown
Investor Context
Institutional InvestorsInvestment Context
This stakeholder is listed as an Institutional Investor within Institutional Investors. Its public geography context is global. Public stage signals include Growth / Late Stage, Public Markets, and Multi-Stage. Public focus areas include Drug Development.
Johnson & Johnson is best understood as a strategic corporate healthcare platform with broad exposure to neuroscience, oncology, immunology, and medical technology. It is not a traditional institutional investor, but it does make large strategic acquisitions and operates an internal venture arm through Johnson & Johnson Innovation – JJDC. That combination makes it relevant to psychedelic-adjacent markets where psychiatric, neurological, and clinical-stage drug development intersect with J&J’s core R&D and commercialization strengths.
Investor Type
Institutional Investor
Geographic Scope
Global
Psychedelic Focus
Psychedelic-Adjacent Focus
Engagement
Active
Investment Stage Focus
Investment Focus Areas
Quick Facts
- Type
- Big Pharma
- Founded
- 1886
- HQ
- United States
- Website
- Visit